177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

← catalyst calendar

NCT06305962 · readout ≤ 499 d

Sponsored by Radiopharm Theranostics, Ltd (industry) · RADX — their whole pipeline →.

Phase

Early Phase 1

Status

Recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

30estimated

Sites

Country

Australia

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-06-03

actual

When the study began enrolling

Primary completion

Dec 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Dec 2027

estimated

The whole study's end, after follow-up

First posted

2024-03-12

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-02-19

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

PDL1 Gene Mutation
Non Small Cell Lung Cancer
Small Cell Lung Cancer ( SCLC )
TNBC, Triple Negative Breast Cancer
Cutaneous Melanoma
HNSCC
Endometrial Cancer
Mmr Deficiency
MSI-High

Intervention

Drug: 177Lu-RAD204

Primary outcomes

what the primary-completion date above is the date OF

Time Activity Curves (TACs)

measured 72 hours

Radiation dosimetry of Lu177-RAD204im

measured 72 hours

Pharmacokinetics of 177Lu-RAD204im

measured 72 hours

Biokinetics of 177Lu-RAD204im

measured 72 hours

Safety and tolerability of 177Lu-RAD204tr

measured 6 weeks

Recommended dose(s) of 177Lu-RAD204tr for future exploration

measured 6 weeks

Permalink · RADX's whole pipeline · Catalyst calendar · Every registered study · What changed